

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

CD44

RRID:AB_2739963

Type: Antibody

Proper Citation

BD Biosciences Cat# 740215, RRID:AB_2739963

Antibody Information

URL: http://antibodyregistry.org/AB_2739963

Proper Citation: BD Biosciences Cat# 740215, RRID:AB_2739963

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD44

Description: This monoclonal targets CD44

Target Organism: mouse

Clone ID: IM7

Antibody ID: AB_2739963

Vendor: BD Biosciences

Catalog Number: 740215

Record Creation Time: 20231110T033515+0000

Record Last Update: 20260831T212336+0000

Ratings and Alerts

No rating or validation information has been found for CD44.

No alerts have been found for CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Maltez VI, et al. (2026) Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment. *Immunity*, 59(4), 1058.

Al Souz J, et al. (2026) Organ injury in systemic autoimmunity is mediated by stem-like CD8+ T cells arising from tissue-draining lymph nodes. *Immunity*, 59(6), 1667.

Isshiki Y, et al. (2025) EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. *Cancer cell*, 43(1), 49.

Amon L, et al. (2025) GM-CSF and specific type 2 cytokines induce CD103+ and CD301b+ cell states in cDC1s and cDC2s. *Cell reports*, 44(12), 116589.

Barisic D, et al. (2024) ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. *Cancer cell*.

Memon D, et al. (2024) Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. *Cancer cell*, 42(2), 209.

Ngiow SF, et al. (2024) LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. *Cell*, 187(16), 4336.

Englebert K, et al. (2024) The CD27/CD70 pathway negatively regulates visceral adipose tissue-resident Th2 cells and controls metabolic homeostasis. *Cell reports*, 43(3), 113824.

Mannion J, et al. (2024) A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. *Immunity*, 57(7), 1514.

Le Moine M, et al. (2023) Homeostatic PD-1 signaling restrains EOMES-dependent oligoclonal expansion of liver-resident CD8 T cells. *Cell reports*, 42(8), 112876.

Virassamy B, et al. (2023) Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. *Cancer cell*, 41(3), 585.

Beltra JC, et al. (2023) Stat5 opposes the transcription factor Tox and rewires exhausted CD8+ T cells toward durable effector-like states during chronic antigen exposure. *Immunity*, 56(12), 2699.

Baxter AE, et al. (2023) The SWI/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8+ T cells. *Immunity*, 56(6), 1320.

Kharel A, et al. (2023) Loss of PBAF promotes expansion and effector differentiation of CD8+ T cells during chronic viral infection and cancer. *Cell reports*, 42(6), 112649.

Kumagai S, et al. (2022) Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. *Cancer cell*, 40(2), 201.

Zander R, et al. (2022) Delineating the transcriptional landscape and clonal diversity of virus-specific CD4+ T cells during chronic viral infection. *eLife*, 11.

DiPiazza AT, et al. (2021) COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. *Immunity*, 54(8), 1869.

Melo-Silva CR, et al. (2021) Resistance to lethal ectromelia virus infection requires Type I interferon receptor in natural killer cells and monocytes but not in adaptive immune or parenchymal cells. *PLoS pathogens*, 17(5), e1009593.

Oh E, et al. (2021) Syntaxin 4 Enrichment in β -Cells Prevents Conversion to Autoimmune Diabetes in Non-Obese Diabetic (NOD) Mice. *Diabetes*, 70(12), 2837.

Dai B, et al. (2021) Dual targeting of lymphocyte homing and retention through $\alpha 4\beta 7$ and $\alpha E\beta 7$ inhibition in inflammatory bowel disease. *Cell reports. Medicine*, 2(8), 100381.